Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yale Univ. School of Medicine MKP5 compound 1
- Development stage
- Unknown
- Lead developer
- Yale School of Medicine
01
Overview
Yale Univ. School of Medicine MKP5 compound 1: sourced facts only. name: "In previous work, we identified Compound 1 (3,3-dimethyl-1-((9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one) as the lead compound of a novel class of MKP5 inhibitors." [PMID:36116232]; target: "In previous work, we identified Compound 1 (3,3-dimethyl-1-((9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one) as the lead compound of a novel class of MKP5 inhibitors." [PMID:36116232]; developer: "Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA." [PMID:36116232]
02
Targets
DUSP5 (Dual specificity protein phosphatase 5)
Beyond the preview
Go deeper on Yale Univ. School of Medicine MKP5 compound 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yale Univ. School of Medicine MKP5 compound 1.